Background: c-erbB-2 is a receptor tyrosine kinase. It exhibits extracellular domains with two cysteine-rich sequences, and a cytoplasmic tyrosine kinase domain flanked by large hydrophilic tails that carry several tyrosine autophosphorylation sites. Approximately 25% of primary breast and ovarian tumors were found to overexpress the protein.
Positive Control: Breast carcinomas.
Immunogen: Full-length recombinant c-erbB-2/HER2/neu protein.
Purification Method: Ammonium Sulfate Precipitation.
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide.
References: 1. Stancovski, I et. al. 'Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.' Proc. Natl. Acad. Sci USA, 1991, 88(19):8691-5.
2. Hurwitz E et. al. 'Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.' Proc. Natl. Acad. Sci USA, 1995, 92(8):3353-7.
UniProt: P04626.
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
English
Deutsch
